Bristol-Myers Squibb (NYSE:BMY – Get Rating) – Research analysts at William Blair cut their FY2023 earnings per share (EPS) estimates for Bristol-Myers Squibb in a research note issued on Monday, April 18th. William Blair analyst M. Phipps now expects that the biopharmaceutical company will post earnings of $7.83 per share for the year, down from their previous forecast of $7.88. William Blair also issued estimates for Bristol-Myers Squibb’s FY2024 earnings at $7.87 EPS, FY2025 earnings at $7.97 EPS and FY2026 earnings at $7.73 EPS.
Bristol-Myers Squibb (NYSE:BMY – Get Rating) last posted its quarterly earnings data on Friday, February 4th. The biopharmaceutical company reported $1.83 earnings per share for the quarter, hitting the consensus estimate of $1.83. Bristol-Myers Squibb had a net margin of 15.08% and a return on equity of 45.60%. The firm had revenue of $11.96 billion during the quarter, compared to analysts’ expectations of $12 billion. During the same quarter in the previous year, the company posted $1.46 EPS. Bristol-Myers Squibb’s revenue was up 8.0% on a year-over-year basis.
BMY stock opened at $76.40 on Wednesday. The company has a debt-to-equity ratio of 1.10, a current ratio of 1.52 and a quick ratio of 1.43. The company has a 50 day moving average price of $71.19 and a 200 day moving average price of $64.13. Bristol-Myers Squibb has a fifty-two week low of $53.22 and a fifty-two week high of $78.13. The stock has a market capitalization of $166.53 billion, a PE ratio of 24.49, a price-to-earnings-growth ratio of 1.47 and a beta of 0.55.
Several institutional investors have recently bought and sold shares of BMY. Mizuho Securities Co. Ltd. boosted its stake in shares of Bristol-Myers Squibb by 239.0% during the 1st quarter. Mizuho Securities Co. Ltd. now owns 339 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 239 shares during the last quarter. PFG Private Wealth Management LLC acquired a new position in shares of Bristol-Myers Squibb during the 3rd quarter worth about $27,000. Bell Investment Advisors Inc acquired a new position in shares of Bristol-Myers Squibb during the 3rd quarter worth about $29,000. Steward Financial Group LLC acquired a new position in shares of Bristol-Myers Squibb during the 4th quarter worth about $29,000. Finally, Horan Securities Inc. acquired a new position in shares of Bristol-Myers Squibb during the 4th quarter worth about $29,000. Institutional investors own 72.00% of the company’s stock.
In related news, EVP Christopher S. Boerner sold 29,532 shares of the company’s stock in a transaction on Monday, March 14th. The shares were sold at an average price of $69.20, for a total value of $2,043,614.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Giovanni Caforio sold 30,000 shares of the company’s stock in a transaction on Thursday, February 24th. The stock was sold at an average price of $67.00, for a total transaction of $2,010,000.00. The disclosure for this sale can be found here. Insiders sold a total of 165,668 shares of company stock valued at $11,459,888 in the last three months. 0.09% of the stock is owned by company insiders.
The company also recently declared a quarterly dividend, which will be paid on Monday, May 2nd. Stockholders of record on Friday, April 1st will be issued a $0.54 dividend. This represents a $2.16 annualized dividend and a dividend yield of 2.83%. The ex-dividend date of this dividend is Thursday, March 31st. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 69.23%.
Bristol-Myers Squibb Company Profile (Get Rating)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.
- Get a free copy of the StockNews.com research report on Bristol-Myers Squibb (BMY)
- Is Turning Point Therapeutics Stock at a Turning Point?
- Buy Haliburton On Post-Earnings Weakness
- Constellation Brands Stock is Launching Towards New Highs
- 3 Analyst Favorite Blue-Chip Stocks to Buy Now
- Does PNC Financial Stock Belong in Your Portfolio?
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.